Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept as Surgical Adjuvant in PDR
NCT01805297Phase 2Completed
- Sponsor
- University of Oklahoma
- Start
- Mar 2013
- Primary completion
- Feb 2014
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aflibercept in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by University of Oklahoma. Primary endpoint: Rate of Resolved Post-operative Vitreous Hemorrhage at 24 weeks. Started Mar 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT01805297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01805297.